Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell LineHaruo Miyata(Shizuoka Cancer Center), Yasuto Akiyama(Shizuoka Cancer Center)Cancer Genomics & ProteomicsJanuary 1, 201710.21873/cgp.20021Cited by 41SaveCiteExport RISWatch citationsRelated PapersYKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line|Oncology Reports|2014|36<i>In Vivo</i>Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models|In Vivo|2024|1Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model|Scientific Reports|2025|1